Work

Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.1074

Authors: Eleanor Meisner, Rebecca Rollins, Joe Ensor, Amber Moran, Amanda Woodward, Eugene R Ahn, Cynthia Anne Lynch, Dennis L. Citrin, Damien Hansra, Sramila S. Aithal, Mary Ninan, Daniel W. Nixon, Susan Zook, Siraj Mahamed Ali, Maurie Markman, Ricardo H. Alvarez

Institutions: University of Illinois Chicago, Rockford campus, Cancer Treatment Centers of America, Houston Methodist, Sylvester Comprehensive Cancer Center, Veterans Health Administration, Morehouse School of Medicine, Foundation Medicine (United States)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2806835116

Cites:

Cited by: 2

Related to: 10